TY - JOUR
T1 - The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO)
AU - Quigley, Eamonn M.M.
N1 - Funding Information:
Funding This study is supported, in part, by a bequest from the Hughes-Sterling Foundation.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose of Review: To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO). Recent Findings: While various series continue to illustrate the occurrence of SIBO in disease states where well-known risk factors for its occurrence are present (hypochlorhydria, disorders of intestinal structure or motor function, pancreatic insufficiency, and chronic liver disease, for example), the current challenge is in defining the limits of SIBO. Is SIBO truly common among those with “functional” gastrointestinal symptoms where there is no evidence of maldigestion or malabsorption; the original hallmarks of SIBO? Our attempts to address this question continue to be hampered by the limitations of our diagnostic tool kit. There is hope—the application of modern molecular techniques to the study of the small intestinal microbiome, together with some innovative sampling techniques, such as real-time intestinal gas sampling, may soon allow us to truly define the spectrum of SIBO. Summary: SIBO, once removed from its original confines as a cause of malabsorption syndrome, has proven to be an elusive and moving target. Only the most rigorous studies employing validated methodologies will finally corral this mysterious entity.
AB - Purpose of Review: To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO). Recent Findings: While various series continue to illustrate the occurrence of SIBO in disease states where well-known risk factors for its occurrence are present (hypochlorhydria, disorders of intestinal structure or motor function, pancreatic insufficiency, and chronic liver disease, for example), the current challenge is in defining the limits of SIBO. Is SIBO truly common among those with “functional” gastrointestinal symptoms where there is no evidence of maldigestion or malabsorption; the original hallmarks of SIBO? Our attempts to address this question continue to be hampered by the limitations of our diagnostic tool kit. There is hope—the application of modern molecular techniques to the study of the small intestinal microbiome, together with some innovative sampling techniques, such as real-time intestinal gas sampling, may soon allow us to truly define the spectrum of SIBO. Summary: SIBO, once removed from its original confines as a cause of malabsorption syndrome, has proven to be an elusive and moving target. Only the most rigorous studies employing validated methodologies will finally corral this mysterious entity.
KW - Breath testing
KW - Hydrogen methane
KW - Microbiome
KW - Rifaximin
KW - Small intestinal bacterial overgrowth
UR - http://www.scopus.com/inward/record.url?scp=85060036232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060036232&partnerID=8YFLogxK
U2 - 10.1007/s11894-019-0671-z
DO - 10.1007/s11894-019-0671-z
M3 - Review article
C2 - 30645678
AN - SCOPUS:85060036232
SN - 1522-8037
VL - 21
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
IS - 1
M1 - 3
ER -